pirotinib (KBP-5209) / Sihuan Pharmaceutical  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pirotinib (KBP-5209) / Sihuan Pharmaceutical
NCT02442414: A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Completed
1
35
US
KBP-5209
Sihuan Pharmaceutical Holdings Group Ltd., Covance, XuanZhu Pharma Co., Ltd.
Advanced Solid Tumors
11/19
11/19

Download Options